MedTrace Logo

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

NCT01630733 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 664

Last updated 2026-04-15

No results posted yet for this study

Summary

The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.

Conditions

Interventions

DRUG

Custirsen

DRUG

Docetaxel

Sponsors & Collaborators

  • Achieve Life Sciences

    lead INDUSTRY

Principal Investigators

  • Joachim Von Pawel, MD · Asklepios Fachkliniken GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-24
Primary Completion
2016-11-17
Completion
2016-11-17

Countries

  • United States
  • Australia
  • Germany
  • Hungary
  • Israel
  • Italy
  • New Zealand
  • Poland
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01630733 on ClinicalTrials.gov